Postmenopausal women w/ osteoporosis at high risk for fracture. Increase of bone mass in men w/ primary or hypogonadal osteoporosis at high risk for fracture. Osteoporosis associated w/ sustained systemic glucocorticoid therapy at high risk for fracture.
Hypersensitivity. Preexisting hypercalcaemia; metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism & Paget's disease of bone); unexplained elevations of alkaline phosphatase; prior external beam or implant radiation therapy to the skeleton; patients w/ skeletal malignancies or bone metastases. Severe renal impairment.
Not to be prescribed for patients at increased baseline risk for osteosarcoma including those w/ Paget's disease of bone or unexplained elevations of alkaline phosphatase, or prior external beam or implant radiation therapy involving the skeleton. Isolated episodes of transient orthostatic hypotension. May increase urinary Ca excretion. Patients w/ active or recent urolithiasis; hepatic, renal & cardiac disease. Concomitant use w/ digitalis. Refrain from driving or the use of machines until symptoms (eg, transient, orthostatic hypotension or dizziness) have subsided. Moderate renal impairment. Not to be used during pregnancy & lactation, in ped patients or young adults w/ open epiphyses.